A Multi-center, Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of the Prophylactic Use of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor After Chemotherapy in Children With Hematological Malignancies
Latest Information Update: 07 Jul 2022
At a glance
- Drugs Pegfilgrastim (Primary) ; Filgrastim
- Indications Chemotherapy-induced damage; Neutropenia
- Focus Therapeutic Use
- Sponsors CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- 05 Aug 2020 New trial record